Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received Nasdaq deficiency notice for failing to maintain minimum $2.5M stockholders' equity requirement, now at risk of delisting.
Transcode Therapeutics receives Nasdaq delisting warning over equity deficiency
Filed May 22, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified RNAZ on May 19, 2026 that its stockholders' equity of $1.25M falls 50% short of the $2.5M minimum required for continued listing on Nasdaq Capital Market.
Item 3.01 verify on EDGAR → -
high
Company has until July 3, 2026 (45 days) to submit a compliance plan. If accepted, Nasdaq may grant up to 180 additional days to regain compliance through equity raises, improved operations, or other measures.
Item 3.01 verify on EDGAR → -
high
Company warns Nasdaq may reject its compliance plan, and even if accepted, it may be unable to restore required equity levels during the extension period.
Item 3.01 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade RNAZ commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 24, 2026 · How we verify